Expertise in
1
conditions

Dr. Matthew Davis

Family Medicine
Office
500 Helendale Rd Ste L20, 
Rochester, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
1
conditions
Office
500 Helendale Rd Ste L20, 
Rochester, NY 

Overview

Matthew Davis is a primary care provider, practicing in Family Medicine in Rochester, New York. Dr. Davis is highly rated in 1 condition, according to our data. His top areas of expertise are Migraine, Parainfluenza, Headache, and Osteomyelitis.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 35 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Family Medicine

Licenses

Family Medicine in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

Office
500 Helendale Rd Ste L20, Rochester, NY 14609

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Biological
Study Drug: RSVPreF3 OA investigational vaccine
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Biological, Drug
Study Drugs: RSVPreF3, Boostrix-ex-US, Boostrix-US
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

15 Total Publications

Secondary Pneumococcal Disease in Veterans with Viral Respiratory Infections.
Secondary Pneumococcal Disease in Veterans with Viral Respiratory Infections.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 20, 2025
Similar Doctors
Expertise in
24
conditions
Dr. Robert Anderson
Family Medicine
Expertise in
24
conditions
Dr. Robert Anderson
Family Medicine

Crooked Lake Family Medicine

1930 Pre Emption Rd, 
Penn Yan, NY 
 (43.7 miles away)
315-536-0086
Experience:
18+ years
Languages Spoken:
English
See accepted insurances

Robert Anderson is a primary care provider, practicing in Family Medicine in Penn Yan, New York. Dr. Anderson has been practicing medicine for over 18 years is highly rated in 24 conditions, according to our data. His top areas of expertise are Paroxysmal Supraventricular Tachycardia (PSVT), Ventricular Tachycardia, Ventricular Fibrillation, Hypertension, and Cardiac Ablation.

Expertise in
2
conditions
Dr. Bradley Turner
Family Medicine
Expertise in
2
conditions
Dr. Bradley Turner
Family Medicine

Office

2745 W Ridge Rd, 
Rochester, NY 
 (8.2 miles away)
585-225-5252
Languages Spoken:
English
See accepted insurances

Bradley Turner is a primary care provider, practicing in Family Medicine in Rochester, New York. Dr. Turner is highly rated in 2 conditions, according to our data. His top areas of expertise are HER2 Negative Breast Cancer, Breast Cancer, Primary Lateral Sclerosis, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease).

Expertise in
4
conditions
Dr. Kevin Kless
Family Medicine
Expertise in
4
conditions
Dr. Kevin Kless
Family Medicine

Compeer Rochester Inc.

259 Monroe Ave, 
Rochester, NY 
 (3.4 miles away)
585-545-7200
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Kevin Kless is a primary care provider, practicing in Family Medicine in Rochester, New York. Dr. Kless has been practicing medicine for over 17 years is highly rated in 4 conditions, according to our data. His top areas of expertise are Gonorrhea, Syphilis, Opioid Use Disorder, and Attention Deficit Hyperactivity Disorder (ADHD).

Frequently Asked Questions about Dr. Matthew Davis

How do I make an appointment with Dr. Matthew Davis?

You can book an appointment with Dr. Matthew Davis by calling their office at 585-288-0890. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Matthew Davis a top-rated expert for Migraine?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthew Davis is classified as an Advanced expert for Migraine, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthew Davis specialize in?

While Dr. Matthew Davis is a Family Medicine, they have specific expertise in Migraine, Parainfluenza, and Headache. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. Matthew Davis participate in research or clinical trials?

Yes. Dr. Matthew Davis has published 15 articles and abstracts on conditions like Migraine. You can view a list of Dr. Matthew Davis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthew Davis accept my insurance?

Dr. Matthew Davis accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 585-288-0890 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Davis's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile